A third dose of the BNT162b2 mRNA vaccine sufficiently improves the neutralizing activity against SARS-CoV-2 variants in liver transplant recipients.

ABSTRACT:

Introduction

We examined the neutralizing antibody production efficiency of the second and third severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine doses (2^nd- and 3^rd-dose) and neutralizing activity on mutant strains, including, the Ancestral, Beta and Omicron strains using green fluorescent protein-carrying recombinant SARS-CoV-2, in living-donor liver transplantation (LDLT) recipients.

Methods

The patients who were administered vaccines other than Pfizer- BioNTechBNT162b2 and who had coronavirus disease 2019 in this study period were excluded. We enrolled 154 LDLT recipients and 50 healthy controls.

Result

The median time were 21 days (between 1^st and 2^nd vaccination) and 244 days (between 2^nd

SUBMITTER: Tomiyama T 

PROVIDER: S-EPMC10229048 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature